- Home
- Publications
- Publication Search
- Publication Details
Title
Does cardiovascular risk matter in IBD patients?
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-30
DOI
10.1111/joim.13735
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
- (2023) Pablo A. Olivera et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
- (2023) Mohamed Attauabi et al. EClinicalMedicine
- High Burden of Obesity and Low Rates of Weight Loss Pharmacotherapy in Inflammatory Bowel Disease: 10-Year Trend
- (2023) Abbinaya Elangovan et al. Crohns Colitis 360
- Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
- (2023) Stefan Schreiber et al. Journal of Crohns & Colitis
- Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review
- (2022) M. Ellen Kuenzig et al. GASTROENTEROLOGY
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data from a Large Tertiary Center
- (2022) Nathaniel A. Cohen et al. Clinical Gastroenterology and Hepatology
- Impact of Obesity on Risk of Hospitalization, Surgery and Serious Infection in Biologic-treated Patients with Inflammatory Bowel Diseases: A CA-IBD Cohort Study
- (2022) Phillip Gu et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Obesity is Associated With Increased Risk of Crohn’s disease, but not Ulcerative Colitis: A Pooled Analysis of Five Prospective Cohort Studies
- (2021) Simon S.M. Chan et al. Clinical Gastroenterology and Hepatology
- Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
- (2021) William J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
- (2021) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials
- (2021) Zhao Zhao et al. Frontiers in Immunology
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications
- (2020) Gursimran S. Kochhar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study
- (2020) Mar Pujades-Rodriguez et al. PLOS MEDICINE
- Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases
- (2019) Adam S. Faye et al. Clinical Gastroenterology and Hepatology
- Body mass index and risk of inflammatory bowel disease: A systematic review and dose‐response meta‐analysis of cohort studies of over a million participants
- (2019) Jamal Rahmani et al. Obesity Reviews
- Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
- (2019) William J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis
- (2018) Siddharth Singh et al. PLoS One
- Extended Venous Thromboembolism Prophylaxis After Elective Surgery for IBD Patients
- (2018) Cigdem Benlice et al. DISEASES OF THE COLON & RECTUM
- Inflammation, metaflammation and immunometabolic disorders
- (2017) Gökhan S. Hotamisligil NATURE
- Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia
- (2016) Siew C. Ng et al. GASTROENTEROLOGY
- Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes
- (2016) Siddharth Singh et al. Nature Reviews Gastroenterology & Hepatology
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
- (2016) Alexander T. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Risk of Venous Thromboembolic Events With Corticosteroid vs Biologic Therapy for Inflammatory Bowel Disease
- (2015) Peter D.R. Higgins et al. Clinical Gastroenterology and Hepatology
- The global burden of IBD: from 2015 to 2025
- (2015) Gilaad G. Kaplan Nature Reviews Gastroenterology & Hepatology
- Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
- (2014) John Camm et al. AMERICAN HEART JOURNAL
- Impact of Abdominal Visceral Adipose Tissue on Disease Outcome in Pediatric Crohnʼs Disease
- (2014) Victor Uko et al. INFLAMMATORY BOWEL DISEASES
- An update on the biology of sphingosine 1-phosphate receptors
- (2014) Victoria A. Blaho et al. JOURNAL OF LIPID RESEARCH
- Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease
- (2013) H. Yuhara et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Increasing Weight of Crohnʼs Disease Subjects in Clinical Trials
- (2013) Gordon W. Moran et al. INFLAMMATORY BOWEL DISEASES
- Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies
- (2013) Mathurin Fumery et al. Journal of Crohns & Colitis
- Richness of human gut microbiome correlates with metabolic markers
- (2013) Emmanuelle Le Chatelier et al. NATURE
- Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
- (2013) Alexander T. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort Study
- (2013) Søren Lund Kristensen et al. PLoS One
- Clinical presentation of venous thromboembolism in inflammatory bowel disease
- (2012) Pavol Papay et al. Journal of Crohns & Colitis
- Mesenteric fat—control site for bacterial translocation in colitis?
- (2012) A Batra et al. Mucosal Immunology
- Ratio of Visceral to Subcutaneous Fat Area Is a Biomarker of Complicated Crohn's Disease
- (2011) Bara Erhayiem et al. Clinical Gastroenterology and Hepatology
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Unknown
- (2011) Alexander Moschen et al. MOLECULAR MEDICINE
- Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
- (2011) Samuel Z. Goldhaber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor expression
- (2010) A. R. Moschen et al. GUT
- Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease 12
- (2010) Millie D. Long et al. INFLAMMATORY BOWEL DISEASES
- Sphingosine-1-phosphate receptor signalling in the heart
- (2009) C. K. Means et al. CARDIOVASCULAR RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More